Investor Michael Burry has increased his position in Zoetis, as the animal health company advances 12 pipeline candidates targeting unmet medical needs while navigating competitive pressures and safety concerns around some companion animal osteoarthritis products. Zoetis recently launched Lenivia for canine osteoarthritis pain in Canada and the EU, expanding its OA toolkit beyond Librela at a time when safety perceptions and competitive threats are under scrutiny. The company's narrative projects $10.7 billion in revenue and $3.1 billion in earnings by 2029, requiring 3.9% yearly revenue growth and an earnings increase of about $0.4 billion from $2.7 billion today. Some optimistic analysts had forecast up to $11.3 billion in revenue and $3.3 billion in earnings by 2029, relying heavily on stronger OA adoption than seen so far. The upcoming earnings report remains the key short-term catalyst, with the main risk centered on safety concerns and competition in OA pain products.
Zoetis IncPipeline expansion and new product launch are positive, but safety concerns and competition create uncertainty.